TrialsgrambetaRCTs are beautiful

EPIC-HR

2022

Nirmatrelvir-Ritonavir in High-Risk Outpatients with COVID-19

In 2,246 high-risk unvaccinated adults with COVID-19, nirmatrelvir-ritonavir within 5 days of symptom onset reduced COVID-19-related hospitalisation or death by day 28 compared with placebo.

Result

Hospitalisation or death at 28 days
Absolute difference
5.54 points
Effect estimate

relative reduction89

The absolute difference is derived from the event rates.

Original publication
Subtopic
Outpatient antiviral
Design
Double-blind RCT
Relevance
Important: one of several pillars.
Source
Hammond J, et al. N Engl J Med. 2022;386(15):1397-1408.doi 10.1056/NEJMoa2118542

Discussion & critique

Cornerstone outpatient antiviral. Caveat: efficacy in vaccinated lower-risk patients and drug-drug interactions limit real-world impact.

Discussed in podcasts